RBM5 identified as key regulator of HOXA9 in acute myeloid leukemia

The protein HOXA9 is overexpressed in most acute myeloid leukemia (AML) cases and is associated with poor patient outcomes.

AstraZeneca allocates £650M to boost its UK manufacturing, campus footprint

AstraZeneca is looking to spend £450 million ($827.1 million) to expand its UK vaccine manufacturing site, on top of a £200 budget ($254.4 million) on

March 7, 2024

At JPM, how much health policy talk should we expect?

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in

January 4, 2024

Rare pediatric disease vouchers face uncertain future after September

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.